In human T-cell acute lymphoblastic leukemia (T-ALL) cells, a CRISPR-Cas9 editing tool was used to disrupt TAL1 (SCL) [4] or TRIB1 (TRB1) [35] genes to delineate their biological functions. This evidence concerns the gene TRIB1 and T-cell acute lymphoblastic leukemia.